Idhifa and Cardiac disorder - a phase IV clinical study of FDA data

Summary:

Cardiac disorder is reported as a side effect among people who take Idhifa (enasidenib mesylate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Tylenol, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Cardiac disorder when taking Idhifa. It is created by eHealthMe based on reports of 2,880 people who have side effects when taking Idhifa from the FDA, and is updated regularly.

What is Idhifa?

Idhifa has active ingredients of enasidenib mesylate. eHealthMe is studying from 2,880 Idhifa users. Check the latest studies of Idhifa.

What is Cardiac disorder?

Cardiac disorder is found to be associated with 2,043 drugs and 1,960 conditions by eHealthMe. Check the latest studies of Cardiac disorder.

On Jul, 17, 2026

2,880 people reported to have side effects when taking Idhifa.
Among them, 11 people (0.38%) have Cardiac disorder.

Among these 11 people:

How long have people been on Idhifa when they have Cardiac disorder? *

What is the gender of people who have Cardiac disorder when taking Idhifa? *

female: 50 %
male: 50 %

What is the age of people who have Cardiac disorder when taking Idhifa? *

What are other drugs people take besides Idhifa? *

What are other side effects people have besides Cardiac disorder? *

Hepatitis B: 2 people, 18.18%
Joint Pain: 2 people, 18.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 18.18%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 18.18%
Constipation: 2 people, 18.18%
Dyspnea (difficult or laboured breathing): 2 people, 18.18%
Fatigue (feeling of tiredness): 2 people, 18.18%
Gait Disturbance: 2 people, 18.18%
Head Injury: 2 people, 18.18%
Hepatitis C: 2 people, 18.18%

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 36.36%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 9.09%
Pain: 1 person, 9.09%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 9.09%
Leukaemia (blood or bone marrow cancer): 1 person, 9.09%
Glioma (a type of tumour that starts in the brain or spine): 1 person, 9.09%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Idhifa and have Cardiac disorder?

- Check whether Cardiac disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Idhifa:

Idhifa (2,880 reports)

Cardiac disorder treatments and more:

Cardiac disorder (160,332 reports)

Browse all side effects of Idhifa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiac disorder:

Cardiac disorder (2,043 drugs)

Browse all the conditions that are associated with Cardiac disorder:

Cardiac disorder (1,960 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enasidenib mesylate (the active ingredients of Idhifa) and Idhifa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.